Jones et al., “Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates”; RSC Medicinal Chemistry, Oct 2022

Jones et al., “Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates”; RSC Medicinal Chemistry, Oct 2022

https://doi.org/10.1039/D2MD00239F

2022 EHA – Combining the IAP antagonist, tolinapant, with a DNA hypomethylating agent enhances anti-tumour mechanisms in preclinical models of T-cell lymphoma

View Poster:
Combining the IAP antagonist, tolinapant, with a DNA hypomethylating agent enhances anti-tumour mechanisms in preclinical models of T-cell lymphoma

Introduction
Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1, cIAP2 and XIAP 1, 2, and has demonstrated immunomodulatory properties in pre-clinical models of T cell lymphoma (TCL) 3. In an ongoing Phase 2 trial (NCT02503423), tolinapant has shown activity against highly pre-treated peripheral and cutaneous T-cell lymphoma 4.

Hypomethylating agents (HMAs) have also shown clinical responses in some subsets of PTCL 5, 6, suggesting thar reduction of methylation can deliver efficacy in PTCL. In addition, HMAs and IAP antagonists show immunomodulatory anti-cancer potential in pre-clinical studies.

Here we have investigated the potential for HMA-induced reversal of epigenetic silencing or altered cell signalling to promote the induction of immunogenic forms of cell death (ICD), such as necroptosis, driven by tolinapant treatment in pre-clinical models of T-cell lymphoma (TCL).

References

  1. Johnson C.N. et al.,J. Med. Chem, 2018, 61(16), 7314-7329.
  2. Ward G.A. et al., Mol. Can. Ther., 2018, 17(7), 1381-1391.
  3. Ferrari N. et al., Blood Adv., 2021, 5(20), 4003-4016.
  4. Samaniego F. et al., HematologicalOncology, 2019,37(S2), 527.
  5. Lemonnier F. et al., Blood, 2018, 132(21),2305-2309.
  6. Wong, J. et al., Leukemia, 2022.
  7. Koo G.-B. et al., Cell Res., 2015, 25,707-725.
  8. Ward G.A. et al., Blood(2021) 138 (Supplement 1): 3986
  9. YauH.L. et al., Mol. Cell, 81, 1-15. 

Chan et al., “3D pride without 2D prejudice: Bias-controlled multi-level generative models for structure-based ligand design”; arXiv 2022

Chan et al., “3D pride without 2D prejudice: Bias-controlled multi-level generative models for structure-based ligand design”; arXiv 2022

https://doi.org/10.48550/arXiv.2204.10663

Lea et al., “Cryo-EM diversifies”; Current Opinion in Structural Biology 2022

Lea et al., “Cryo-EM diversifies”; Current Opinion in Structural Biology 2022

https://doi.org/10.1016/j.sbi.2022.102469

St. Denis et al., “X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor”; J. Med. Chem. 2022

St. Denis et al., “X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor”; J. Med. Chem. 2022

https://doi.org/10.1021/acs.jmedchem.2c01044

Tamanini et al., “Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor”; ACS Med. Chem. Lett. 2022

Tamanini et al., “Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor”; ACS Med. Chem. Lett. 2022

https://doi.org/10.1021/acsmedchemlett.2c00272

da Silva Júnior et al., “Growth vector elaboration of fragments: regioselective functionalization of 5-hydroxy-6-azaindazole and 3-hydroxy-2,6-naphthyridine”; Org. Biomol. Chem. 2022

da Silva Júnior et al., “Growth vector elaboration of fragments: regioselective functionalization of 5-hydroxy-6-azaindazole and 3-hydroxy-2,6-naphthyridine”; Org. Biomol. Chem. 2022

https://doi.org/10.1039/D2OB00968D

Priyanka et al., “Mitoxantrone stacking does not define the active or inactive state of USP15 catalytic domain”; J. Struct. Biol. 2022

Priyanka et al., “Mitoxantrone stacking does not define the active or inactive state of USP15 catalytic domain”; J. Struct. Biol. 2022

https://doi.org/10.1016/j.jsb.2022.107862

Izsák et al., “Quantum computing in pharma: A multilayer embedding approach for near future applications”; J. Comput. Chem. 2022

Izsák et al., “Quantum computing in pharma: A multilayer embedding approach for near future applications”; J. Comput. Chem. 2022

https://doi.org/10.1002/jcc.26958

Lu et al., “Enantioselective fullerene functionalization via stereochemical information transfer from a self-assembled cage”; ChemRxiv 2022

Lu et al., “Enantioselective fullerene functionalization via stereochemical information transfer from a self-assembled cage”; ChemRxiv 2022

https://chemrxiv.org/engage/chemrxiv/article-details/62c413cc13b85b01b33f3b77